Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence
Bezlotoxumab (Zinplava™) is a fully human monoclonal antibody against Clostridium difficile toxin B indicated for the prevention of C. difficile infection (CDI) recurrence in patients with a high recurrence risk. It is the first agent approved for recurrence prevention and is administered as a single intravenous infusion in conjunction with standard-of-care (SoC) antibacterial treatment for CDI. In well-designed, placebo-controlled, phase 3 trials (MODIFY 1 and 2), a single infusion of bezlotoxumab, given in combination with SoC antibacterial therapy for CDI in adults, was effective in reducing CDI recurrence in the 12 weeks post-treatment, with this benefit being seen mainly in the patients at high recurrence risk. Bezlotoxumab did not impact the efficacy of the antibacterials being used to treat the CDI and, consistent with its benefits on CDI recurrence, appeared to reduce the need for subsequent antibacterials, thus minimizing further gut microbiota disruption. Longer term, there were no further CDI recurrences over 12 months’ follow-up among patients who had received bezlotoxumab in MODIFY 2 and entered an extension substudy. Bezlotoxumab has low immunogenicity and is generally well tolerated, although the potential for heart failure in some patients requires consideration; cost-effectiveness data for bezlotoxumab are awaited with interest. Thus, a single intravenous infusion of bezlotoxumab during SoC antibacterial treatment for CDI is an emerging option for reducing CDI recurrence in adults at high risk of recurrence.
During the peer review process, the manufacturer of bezlotoxumab was given the opportunity to review this manuscript. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/F0E8F06008C34756.
- 4.Mayo Clinic. C. difficile infection. http://www.mayoclinic.org/diseases-conditions/c-difficile/diagnosis-treatment/treatment/txc-20202426. Accessed 21 Aug 2017.
- 6.Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.CrossRefPubMedGoogle Scholar
- 9.Merck Sharp. Zinplava 25 mg/mL concentrate for solution for infusion: EU summary of product characteristics. 2017. http://www.ema.europa.eu/. Accessed 21 Aug 2017.
- 10.Merck Sharp. Zinplava™ (bezlotoxumab): US prescribing information. 2016. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed 21 Aug 2017.
- 14.Koon HW, Shih DQ, Hing TC, et al. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob Agents Chemother. 2013;57(7):3214–23.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.European Medicines Agency. Assessment report: Zinplava (international non-proprietary name: bezlotoxumab). 2016. http://www.ema.europa.eu. Accessed 21 Aug 2017.
- 19.Merck Research Laboratories. Bezlotoxumab (MK-6072) FDA Antimicrobial Drugs Advisory Committee Meeting. 2016. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm507577.pdf. Accessed 21 Aug 2017.
- 20.Golan Y, Birch T, Rizzardini G, et al. Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for C. difficile infection (CDI) [poster no. Saturday—213]. In: ASM Microbe Meeting; 2017.Google Scholar
- 21.Johnson S, Sambol S, Best E, et al. Efficacy of bezlotoxumab in patients infected with strains of Clostridium difficile associated with poor outcomes [abstract no. 2114]. Open Forum. Infect Dis. 2016;3(Suppl 1):S599.Google Scholar
- 22.Wilcox MH, Rahav G, Dubberke E, et al. Assessment of efficacy of bezlotoxumab for prevention of CDI recurrence (rCDI) by diagnostic test method [abstract no. P1341 plus poster]. In: ECCMID; 2016.Google Scholar
- 23.Golan Y, Dubberke E, Hanson ME, et al. Bezlotoxumab (BZO) decreases recurrence and is associated with a reduction in 30-day Clostridium difficile infection (CDI)-associated readmissions in hospitalized patients with CDI [abstract Monday-449 plus poster]. In: ASM Microbe Meeting; 2016.Google Scholar
- 24.Basu A, Prabhu VS, Marcella S, et al. Bezlotoxumab is associated with a reduction in cumulative hospitalized days: analysis of the hospitalization data from the modify I and II clinical trials [abstract no. 2E−2]. In: Society for Medical Decision Making16th Biennial European Conference; 2016.Google Scholar
- 25.Gerding DN, Kelly CP, Rahav G, et al. Efficacy of bezlotoxumab, the monoclonal antibody targeting C. difficile toxin B, for prevention of C. difficile infection (CDI) recurrence in patients at high risk of recurrence or CDI-related adverse outcomes [abstract no. EP0176]. In: ECCMID; 2016.Google Scholar
- 26.Goldstein E, Citron D, Gerding D, et al. Recurrent Clostridium difficile infection (rCDI) and colonization in the 12 months following administration of bezlotoxumab (BEZ) alone and in combination with actoxumab (ACT). In: ASM Microbe Meeting; 2016.Google Scholar
- 27.Dubberke ER, Gerding D, Kelly C, et al. Efficacy of bezlotoxumab in patients receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridium difficile infection (CDI) [abstract no. 838]. Open Forum Infect Dis. 2016;3(suppl_1).Google Scholar
- 28.Lee C, Graham DR, Wilcox MH, et al. Bezlotoxumab for prevention of C. difficile infection (CDI) recurrence in participants receiving antibacterial therapy for CDI: use of antibacterial therapy for CDI and fecal microbiota transplant in the MODIFY trials [poster Sunday 244]. In: ASM Microbe Meeting; 2017.Google Scholar